Cidara Therapeutics Inc
NASDAQ:CDTX
Cidara Therapeutics Inc
Inventory
Cidara Therapeutics Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cidara Therapeutics Inc
NASDAQ:CDTX
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Inventory
$5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Inventory
$1.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Inventory
$6.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Inventory
$1.7B
|
CAGR 3-Years
54%
|
CAGR 5-Years
43%
|
CAGR 10-Years
40%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Inventory
$2.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
26%
|
|
Cidara Therapeutics Inc
Glance View
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. The company is headquartered in San Diego, California and currently employs 89 full-time employees. The company went IPO on 2015-04-15. The firm is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The firm's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin acetate is in Phase III of chemical trials. Its Cloudbreak antiviral platform consist of pipelines to develop Antiviral Conjugates (AVCs) for the prevention and treatment of influenza and other viral infections, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV) and the SARS-CoV-2 strains causing COVID-19. The firm's subsidiary includes Cidara Therapeutics United Kingdom Limited and Cidara Therapeutics (Ireland) Limited.
